ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: In conclusion, CML-RAE-1γ-Dex treatment inhibited the occurrence and development of CML induced by BCR-ABL with or without the T315I mutation, leading to a notable improvement in the overall survival of CML mice.